Pharmacological caspase inhibitors: Research towards therapeutic perspectives

Journal of Physiology and Pharmacology

Volumn 66, Issue 4, 2015, Pages 473-482

  Kudelova, J ^a   Fleischmannova, J ^b,c   Adamova, E ^b,d   Matalova, E ^b,e  

^a UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^e INSTITUTE OF ANALYTICAL CHEMISTRY   (Czech Republic)

Author keywords

Apoptosis; Caspase; Caspase inhibitor; Central nervous system; Inflammation; Ischaemia reperfusion injury

Indexed keywords

BELNACASAN; CASPASE; CASPASE INHIBITOR; EMRICASAN; NCX 1000; NIVOCASAN; PRALNACASAN; UNCLASSIFIED DRUG; Z VAD FMK;

APOPTOSIS; AUTOIMMUNE DISEASE; CELL DEATH; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; DRUG SPECIFICITY; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; LIVER INJURY; LUNG DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; SEPSIS; TRAUMATIC BRAIN INJURY; UPREGULATION; ANIMAL; DRUG EFFECTS; METABOLISM;

ANIMALS; APOPTOSIS; CASPASE INHIBITORS; CASPASES; HUMANS; INFLAMMATION;

EID: 84940744287     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999; 96: 245-254.
2. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
3. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem 2009; 284: 21777-81.
4. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005; 258: 479-517.
5. Favaloro B, Allocati N, Graziano V, Di Ilio C, De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY) 2012; 4: 330-349.
6. Ratziu V, Sheikh MY, Sanyal AJ, et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with non-alcoholic steatohepatitis. Hepatology 2012; 55: 419-428.
7. McCall MD, Maciver AM, Kin T, et al. Caspase inhibitor IDN6556 facilitates marginal mass islet engraftment in a porcine islet auto-transplant model. Transplantation 2012; 94: 30-35.
8. Hacker HG, Sisay MT, Gutschow M. Allosteric modulation of caspases. Pharmacol Ther 2011; 132: 180-195.
9. Gao J, Wells JA. Identification of specific tethered inhibitors for caspase-5. Chem Biol Drug Des 2012; 79: 209-215.
10. Callus BA, Vaux DL. Caspase inhibitors: viral, cellular and chemical. Cell Death Differ 2007; 14: 73-78.
11. Ullman BR, Aja T, Deckwerth TL, et al. Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications. Bioorg Med Chem Lett 2003; 13: 3623-3626.
12. Vandenabeele P, Vanden Berghe T, Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006; 2006 (358): pe44.
13. Van Noorden CJF. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem 2001; 103: 241-251.
14. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad spectrum caspase inhibitor with potent anti-apoptotic properties. Apoptosis 2003; 8: 345-352.
15. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005; 57: 187-215.
16. Asgian JL, James KE, Li ZZ, et al. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases. J Med Chem 2002; 45: 4958-4860.
17. James KE, Asgian JL, Li ZZ, et al. Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8. J Med Chem 2004; 47: 1553-1574.
18. Leyva MJ, Degiacomo F, Kaltenbach LS, et al. Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem Biol 2010; 17: 11891200. Erratum in: Chem Biol 2013; 20: 742.
19. Huber KL, Ghosh S, Hardy JA. Inhibition of caspase-9 by stabilized peptides targeting the dimerization interface. Biopolymers 2012; 98: 451-465.
20. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells JA. Discovery of an allosteric site in the caspases. Proc Natl Acad Sci USA 2004; 101: 12461-12466.
21. Feldman T, Kabaleeswaran V, Jang SB, et al. A class of allosteric caspase inhibitors identified by high-throughput screening. Mol Cell 2012; 47: 585-595.
22. Masuoka HC, Guicciardi ME, Gores GJ. Caspase inhibitors for the treatment of hepatitis C. Clin Liver Dis 2009; 13: 467-475.
23. Witek RP, Stone WC, Karaca FG, et al. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009; 50: 1421-1430.
24. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996; 184: 2067-2072.
25. Cai SX, Guan LF, Jia SJ, et al. Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group. Bioorg Med Chem Lett 2004; 14: 5295-5300.
26. Rouquet N, Pages JC, Molina T, Briand P, Joulin V. ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis. Curr Biol 1996; 6: 1192-1195.
27. Rudolphi K, Gerwin N, Verzijl N, van der Kraan P, van den Berg W. Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage 2003; 11: 738-746.
28. Le GT, Abbenante G. Inhibitors of TACE and caspase-1 as anti-inflammatory drugs. Curr Med Chem 2005; 12: 2963-2977.
29. Iwata A, Nishio K, Winn RK, Chi EY, Henderson WR Jr, Harlan JM. A broad-spectrum caspase inhibitor attenuates allergic airway inflammation in murine asthma model. JImmunol 2003; 170: 3386-3391.
30. Kuwano K, Hagimoto N, Hara N. Molecular mechanisms of pulmonary fibrosis and current treatment. Curr Mol Med. 2001; 1: 551-573.
31. Catalan MP, Esteban J, Subira D, Egido J, Ortiz A. Inhibition of caspases improves bacterial clearance in experimental peritonitis. Perit Dial Int 2003; 23: 123-126.
32. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 1999; 5: 298-302.
33. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999; 96: 14541-14546.
34. Hotchkiss RS, Dunne WM, Swanson PE, et al. Role of apoptosis in Pseudomonas aeruginosa pneumonia. Science 2001; 294: 1783.
35. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4(+) T lymphocytes in humans. J Immunol 2001; 166: 6952-6963.
36. Wesche-Soldato DE, Lomas-Neira JL, Perl M, Jones L, Chung CS, Ayala A. The role and regulation of apoptosis in sepsis. J Endotoxin Res 2005; 11: 375-382.
37. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1: 496-501.
38. Methot N, Huang JQ, Coulombe N, et al. Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics. J Exp Med 2004; 199: 199-207.
39. Fauvel H, Marchetti P, Chopin C, Formstecher P, Neviere R. Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. Am J Physiol Heart Circul Physiol 2001; 280: H1608-H1614.
40. Oberhotzer C, Tschoeke SK, Moldawer LL, Oberholzer A. Local thymic caspase-9 inhibition improves survival during polymicrobial sepsis in mice. J Mol Med 2006; 84: 389-395.
41. Kang SJ, Wang S, Kuida K, Yuan J. Distinct downstream pathways of caspase-11 in regulating apoptosis and cytokine maturation during septic shock response. Cell Death Differ 2002; 9: 1115-1125.
42. Saleh M, Mathison JC, Wolinski MK, et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 2006; 440: 1064-1068.
43. Weber P, Wang P, Maddens S, et al. VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Crit Care 2009; 13: R136.
44. Cursio R, Gugenheim J, Ricci JE, et al. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB J 1999; 13: 253-261.
45. Quadri SM, Segall L, de Perrot M, et al. Caspase inhibition improves ischemia-reperfusion injury after lung transplantation. Am J Transplant 2005; 5: 292-299.
46. Okamura T, Miura T, Takemura, et al. Effect of caspase inhibitors on myocardial infarct size and myocyte DNA fragmentation in the ischaemia-reperfused rat heart. Cardiovasc Res 2000; 45: 642-650.
47. Chatterjee PK, Todorovic Z, Sivarajah A, et al. Differential effects of caspase inhibitors on the renal dysfunction and injury caused by ischemia-reperfusion of the rat kidney. Eur J Pharmacol 2004; 503: 173-183.
48. Cheng Y, Deshmukh M, D'Costa A, et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. J Clin Invest 1998; 101: 1992-1999.
49. Wiessner C, Sauer D, Alaimo D, Allegrini PR. Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell Mol Biol (Noisy le grand) 2000; 46: 53-62.
50. Chapman JG, Magee WP, Stukenbrok HA, Beckius GE, Milici AJ, Tracey WR. A Novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury. Eur J Pharmacol 2002; 456: 59-68.
51. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor. Circulation 1998; 97: 276-281.
52. Su Q, Li L, Liu YC, Zhou Y, Lu YG, Wen WM. Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. Exp Clin Cardiol 2013; 18: 161-165.
53. Feng YZ, Fratkin JD, LeBlanc MH. Inhibiting caspase-9 after injury reduces hypoxic ischemic neuronal injury in the cortex in the newborn rat. Neurosci Lett 2003; 344: 201-204.
54. Han BH, Xu DG, Choi JJ, et al. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J Biol Chem 2002; 277: 30128-30136.
55. Ross J, Brough D, Gibson RM, Loddick SA, Rothwell NJ. A selective, non-peptide caspase-1 inhibitor, VRT-018858, markedly reduces brain damage induced by transient ischemia in the rat. Neuropharmacology 2007; 53: 638-642.
56. Braun JS, Prass K, Dirnagl U, Meisel A, Meisel C. Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH. Exp Neurol 2007; 206: 183-191.
57. Han W, Sun YY, Wang XY, Zhu CL, Blomgren K. Delayed, long-term administration of the caspase inhibitor Q-VD-OPh reduced brain injury induced by neonatal hypoxia-ischemia. Dev Neurosci 2014; 36: 64-72.
58. Carlsson Y, Schwendimann L, Vontell R, et al. Genetic inhibition of caspase-2 reduces hypoxic-ischemic and excitotoxic neonatal brain injury. Ann Neurol 2011; 70: 781-789.
59. Chauvier D, Renolleau S, Holifanjaniaina S, et al. Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor. Cell Death Dis 2011; 2: e203.
60. Venero JL, Burguillos MA, Brundin P, Joseph B. The executioners sing a new song: killer caspases activate microglia. Cell Death Differ 2011; 18: 1679-1691.
61. Fricker M, Vilalta A, Tolkovsky AM, Brown GC. Caspase inhibitors protect neurons by enabling selective necroptosis of inflamed microglia. J Biol Chem 2013; 288: 9145-9152.
62. Knoblach SM, Nikolaeva M, Huang XL, et al. Multiple caspases are activated after traumatic brain injury: evidence for involvement in functional outcome. J Neurotrauma 2002; 19: 1155-1170.
63. Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci 1997; 17: 7415-7424.
64. Clark RS, Kochanek PM, Watkins SC, et al. Caspase-3 mediated neuronal death after traumatic brain injury in rats. JNeurochem 2000; 74: 740-753.
65. Mejia RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery 2001; 48: 1393-1399.
66. Li M, Ona VO, Chen M, et al. Functional role and therapeutic implications of neuronal caspase-1 and-3 in a mouse model of traumatic spinal cord injury. Neuroscience 2000; 99: 333-342.
67. Colak A, Antar V, Karaoglan A, et al. Q-VD-OPh, a pancaspase inhibitor, reduces trauma-induced apoptosis and improves the recovery of hind-limb function in rats after spinal cord injury. Neurocirugia (Astur) 2009; 20: 533-540.
68. Barut S, Unlu YA, Karaoglan A, et al. The neuroprotective effects of z-DEVD.fmk, a caspase-3 inhibitor, on traumatic spinal cord injury in rats. Surg Neurol 2005; 64: 213-220.
69. Akdemir O, Berksoy I, Karaoglan A, et al. Therapeutic efficacy of Ac-DMQD-CHO, a caspase 3 inhibitor, for rat spinal cord injury. J Clin Neurosci 2008; 15: 672-678.
70. Colak A, Karaoglan A, Barut S, Kokturk S, Akyildiz AI, Tasyurekli M. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine 2005; 2: 327-334.
71. Sencer A, Aydoseli A, Aras Y, et al. Effects of combined and individual use of N-methyl-D aspartate receptor antagonist magnesium sulphate and caspase-9 inhibitor z-LEDH-fmk in experimental spinal cord injury. Ulus Travma Acil Cerrahi Derg 2013; 19: 313-319.
72. Monnier PP, D'Onofrio PM, Magharious M, et al. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells. JNeurosci 2011; 31: 10494-10505.
73. Piao CS, Loane DJ, Stoica BA, et al. Combined inhibition of cell death induced by apoptosis inducing factor and caspases provides additive neuroprotection in experimental traumatic brain injury. Neurobiol Dis 2012; 46: 745-758.
74. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1 beta signalling prevents degeneration of retinal capillaries in diabetes galactosaemia. Diabetes 2007; 56: 224-230.
75. Vigneswara V, Berry M, Logan A, Ahmed Z. Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats. PLoS One 2012; 7: e53473.
76. Matsui JI, Haque A, Huss D, et al. Caspase inhibitors promote vestibular hair cell survival and function after aminoglycoside treatment in vivo. J Neurosci 2003; 23: 6111-6122.
77. Abaamrane L, Raffin F, Schmerber S, Sendowski I. Intracochlear perfusion of leupeptin and z-VAD-FMK: influence of anti-apoptotic agents on gunshot-induced hearing loss. Eur Arch Otorhinolaryngol 2011; 268: 987-993.
78. Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 2003; 4: 365-375.
79. Zhao H, Zhao WJ, Lok K, Wang ZJ, Yin M. A synergic role of caspase-6 and caspase-3 in tau truncation at D421 induced by H2O2. Cell Mol Neurobiol 2014; 34: 369-378.
80. Graham RK, Deng Y, Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006; 125: 1179-1191.
81. Li MW, Ona VO, Guegan C, et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-339.
82. Rohn TT, Kokoulina P, Eaton CR, Poon WW. Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh. Int J Clin Exp Med 2009; 2: 300-308.
83. Toulmond S, Tang K, Bureau Y, et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol 2004; 141: 689-697.
84. Emamaullee JA, Stanton L, Schur C, Shapiro AM. Caspase inhibitor therapy enhances marginal mass islet graft survival and preserves long-term function in islet transplantation. Diabetes 2007; 56: 1289-1298.
85. Natori S, Higuchi H, Contreras P, Gores GJ. The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Liver Transpl 2003; 9: 278-284.
86. Hoglen NC, Anselmo DM, Katori M, et al. A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Liver Transpl 2007; 13: 361-366.
87. McCall M, Toso C, Emamaullee J, et al. The caspase inhibitor IDN-6556 (PF3491390) improves marginal mass engraftment after islettransplantation in mice. Surgery 2011; 150: 48-55.
88. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005; 26: 263-70.
89. Siedlecka-Kroplewska K, Jozwik A, Boguslawski W, et al. Pterostilbene induces accumulation of autophagic vacuoles followed by cell death in Hl60 human leukemia cells. J Physiol Pharmacol 2013; 64: 545-56.
90. Toton E, Ignatowicz E, Bernard MK, Kujawski J, Rybczynska M. Evaluation of apoptotic activity of new condensed pyrazole derivatives. J Physiol Pharmacol 2013; 64: 115-123.
91. Kim KW, Moretti L, Lu B. M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. PLoS One 2008; 3: e2275.
92. Moretti L, Kim KW, Jung DK, Willey CD, Lu B. Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Mol Cancer Ther 2009; 8: 1270-1279.
93. Chen-Deutsch X, Kutner A, Harrison JS, Studzinski GP. The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells. LeukRes 2012; 36: 884-888.
94. Sangeetha VM, Kadekar D, Kale VP, Limaye LS. Pharmacological inhibition of caspase and calpain proteases: A novel strategy to enhance the homing responses of cord blood HSPCs during expansion. PLoS One 2012; 7: e29383.
95. Bissoyi A, Nayak B, Pramanik K, Sarangi SK. Targeting cryopreservation-induced cell death: A review. Biopreserv Biobank 2014; 12: 23-34.
96. Yagi T, Hardin JA, Valenzuela YM, Miyoshi H, Gores GJ, Nyberg SL. Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes. Hepatology 2001; 33: 1432-1440.
97. Peter AT, Linde-Forsberg C. Efficacy of the anti-caspase agent zVAD-fmk on post-thaw viability of canine spermatozoa. Theriogenology2003; 59: 1525-1532.
98. Heng BC, Clement MV, Cao T. Caspase inhibitor Z-VAD-FMK enhances the freeze-thaw survival rate of human embryonic stem cells. Biosci Rep 2007; 27: 257-264.
99. Cho HJ, Lee SH, Yoo JJ, Shon YH. Evaluation of cell viability and apoptosis in human amniotic fluid-derived stem cells with natural cryoprotectants. Cryobiology 2014; 68: 244-250.
100. Shiri R, Yari F, Ahmadinejad M, Vaeli S, Tabatabaei MR. The caspase-3 inhibitor (peptide Z-DEVD-FMK) affects the survival and function of platelets in platelet concentrate during storage. Blood Res 2014; 49: 49-53.
101. Loher F, Bauer C, Landauer N, et al. The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation. J Pharmacol Exp Ther 2004; 308: 583-590.
102. URL 1: http://www.evaluategroup.com/Universal/View. aspx?type=Story&id=45867
103. Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethy l-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1 beta and IL-18. J Pharmacol Exp Ther 2007; 321: 509-516.
104. Stack JH, Beaumont K, Larsen PD, et al. IL-converting enzyme/caspase-I inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol 2005; 175: 2630-2634.
105. URL 2: http://investors.vrtx.com/releasedetail.cfm? ReleaseID=555967
106. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013; 103: 2-30.
107. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Int J Clin Pharmacol Ther 2003; 41: 441-449.
108. Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an anti-apoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology2007; 46: 324-329.
109. Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 969-978.
110. URL 3: http://clinicaltrial.gov/ct2/show/NCT01912404 ?term=IDN-6556&rank=2
111. URL 4: http://clinicaltrial.gov/ct2/show/NCT01937130 ?term=IDN-6556&rank=3
112. URL 5: http://clinicaltrial.gov/ct2/show/NCT01653899 ?term=IDN-6556&rank=1
113. Arends JE, Hoepelman AIM, Nanlohy NM, et al. Low doses of the novel caspase-inhibitor GS-9450 leads to lower caspase-3 and -8 expression on peripheral CD4+ and CD8+T-cells. Apoptosis 2011; 16: 959-966.
114. Fiorucci S, Mencarelli A, Palazzetti B, Del Soldato P, Morelli A, Ignarro LJ. An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity. Proc Natl Acad Sci 2001; 98: 2652-2627.
115. Berzigotti A, Bellot P, De Gottardi A, et al. NCX-1000, anitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol 2010; 105: 1094-1101.
116. Van Molle W, Brouckaert P, Libert C. Caspase-1 is not involved in experimental hepatitis in mouse. FEBS Lett 1999; 445: 115-118.
117. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2004; 286: 1923-1935.
118. Mersmann J, Zacharowski PA, Schmitz I, Zacharowski K. Caspase inhibitor zVAD.fmk reduces infarct size after myocardial ischaemia and reperfusion in rats but not in mice. Resuscitation 2008; 79: 468-474.
119. Berger AB, Sexton KB, Bogyo M. Commonly used caspase inhibitors designed based on substrate specificity profiles lack selectivity. Cell Res 2006; 16: 961-963.
120. Heise CE, Murray J, Augustyn KE, et al. Mechanistic and structural understanding of uncompetitive inhibitors of caspase-6. PLoS One 2012; 7: e50864.
121. Nakatsumi H, Yonehara S. Identification of functional regions defining different activity in caspase-3 and caspase-7 within cells. J Biol Chem 2010; 285: 25418-25425.
122. Sharma S, Basu A, Agrawal RK. Pharmacophore modeling and docking studies on some nonpeptide-based caspase-3 inhibitors. BiomedRes Int 2013; 2013: 306081.
123. Wu JH, Wang YR, Liang SG, Ma HC. Cytoprotective effect of selective small-molecule caspase inhibitors against staurosporine-induced apoptosis. Drug Des Devel Ther 2014; 8: 583-600.
124. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003; 4: 387-393.
125. Daemen M, van't Veer C, Denecker G, et al. Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation. J Clin Invest 1999; 104: 541-549.
126. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J Drug Deliv 2011; 2011: 469679.
127. Karatas H, Aktas Y, Gursoy-Ozdemir Y, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 2009; 29: 13761-13769.
128. Svandova E, Lesot H, Vanden Berghe T, et al. Non-apoptotic functions of caspase-7 during osteogenesis. Cell Death Dis 2014; 5: e1366.
129. Maelfait J, Beyaert R. Non-apoptotic functions of caspase-8. Biochem Pharmacol 2008; 76: 1365-1373.
130. Gulyaeva NV. Non-apoptotic functions of caspase-3 in nervous tissue. Biochemistry (Mosc) 2003; 68: 1171-1180.
131. Schwerk C, Schulze-Osthoff K. Non-apoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol 2003; 66: 1453-1458.
132. McDonald J, Wright MR, Wright CD, Kuehl PJ, Duncan M, Doyle-Eisele M. GS-9450-A novel caspase inhibitor provides protection against bleomycin induced pulmonary fibrosis by inhibition of apoptosis. Am J Respir Crit Care Med 2010; 181: A1053.
133. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004; 308: 1191-1196.
134. Maroso M, Balosso S, Ravizza T, et al. Interleukin 1b biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 2011; 8: 304-315.
135. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. Characterization ofIDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther 2004; 309: 634-640.
136. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 2014; 505: 509-514.
137. Schulz JB, Weller M, Matthews RT, et al. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death Differ 1998; 5: 847-857.
138. Yang L, Sugama S, Mischak RP, et al. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis 2004; 17: 250-259.
139. Deckwerth TL, Adams LM, Wiessner C, et al. Long-term protection of brain tissue from cerebral ischemia by peripherally administered peptidomimetic caspase inhibitors. Drug Develop Res 2001; 52: 579-586.
140. Kuwano K, Kunitake R, Maeyama T, et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2001; 280: L316-L325.
141. Montolio M, Tellez N, Biarnes M, Soler J, Montanya E. Short-term culture with the caspase inhibitor z-VAD.fmk reduces beta cell apoptosis in transplanted islets and improves the metabolic outcome of the graft. Cell Transplant 2005; 14: 59-65.